“shared medical appointments”的搜索结果，显示 1151-1160 项，共有 15430 项

  1. 血管中心- 医生 - 妙佑医疗国际

    Share on: FacebookTwitter WeChat. WeChat. Close. Weibo. 血管中心. 部分. 概述 · 测试与程序 · 主治 · 医生 · Doctors by location and specialty · 专业团队 · 临床 ...

  2. Incidentally discovered adrenal masses and subclinical Cushing syndrome - 妙佑医疗国际

    Share; Doximity · Facebook · LinkedIn · Twitter; Print details. MAC-20439148. 医疗专业人员; Incidentally discovered adrenal masses and subclinical Cushing ...

  3. 血管中心- 医生 - 妙佑医疗国际

    Share on: FacebookTwitter WeChat. WeChat. Close. Weibo. 血管中心. 部分. 概述 · 测试与程序 · 主治 · 医生 · Doctors by location and specialty · 专业团队 · 临床 ...

  4. 纤维肌发育不良- 医生与科室- 妙佑医疗国际

    Connect with others like you for support and answers to your questions in the Heart & Blood Health support group on Mayo Clinic Connect, a patient community.

  5. 皮肤 B 细胞淋巴瘤- 诊断与治疗- 妙佑医疗国际

    The concern and understanding of a counselor, medical social worker, clergy member or cancer support group also may be helpful. Ask your healthcare team about ...

  6. 血管中心- 医生 - 妙佑医疗国际

    Share on: FacebookTwitter WeChat. WeChat. Close. Weibo. 血管中心. 部分. 概述 · 测试与程序 · 主治 · 医生 · Doctors by location and specialty · 专业团队 · 临床 ...

  7. 手移植- 临床试验- 妙佑医疗国际

    Study of Potential VCA Candidates', Caregivers' and Providers' Motivations, Expectations and Shared Decision-making in VCA. Rochester, Minn. The purpose of ...

  8. 皮肤科- 临床试验- 妙佑医疗国际

    The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge ...

  9. Cochlear implants Early intervention to optimize language outcomes - 妙佑医疗国际

    Share; Doximity · Facebook · LinkedIn · Twitter; Print details. MAC-20452729. 医疗专业人员; Cochlear implants Early intervention to optimize language outcomes ...

  10. Recurrent primary hyperparathyroidism in a patient with multiple endocrine neoplasia type 1 - 妙佑医疗国际

    Recurrent primary hyperparathyroidism in a patient with multiple endocrine neoplasia type 1. Share; Doximity · Facebook · LinkedIn · Twitter; Print details.